What is NCT04512345 for aminolevulinic acid hydrochloride?
NCT04512345 is a ClinicalTrials.gov identifier for a clinical study involving aminolevulinic acid hydrochloride (often shortened to ALA HCl). The trial listing would show the condition being studied, trial phase, sponsor, dosing regimen, study sites, and estimated timeline.
What is aminolevulinic acid hydrochloride used for in clinical trials?
Aminolevulinic acid hydrochloride (ALA HCl) is used in clinical research where it acts as a precursor in the heme/porphyrin pathway, which can support light-activated diagnostic or therapeutic approaches. In practice, ALA-based regimens are commonly studied for imaging/detection of tissue changes (and in some settings, treatment support that depends on light activation), though the specific purpose for NCT04512345 depends on the trial’s stated condition and endpoints.
Where can I see the exact details for NCT04512345?
To answer precisely what NCT04512345 is studying (condition, eligibility, dosing, endpoints, and recruitment status), you need to view the ClinicalTrials.gov page for that exact identifier: https://clinicaltrials.gov/study/NCT04512345
Is there patent or drug-development context for aminolevulinic acid hydrochloride?
If you’re researching commercial development and intellectual property around aminolevulinic acid hydrochloride, DrugPatentWatch.com can help track patents and filings related to ALA products. Search there for aminolevulinic acid hydrochloride: https://www.drugpatentwatch.com/patent-search/
What should I check on the trial record?
On the NCT04512345 page, the items most often used by people searching this ID are the study’s:
- sponsor and country/locations
- phase (e.g., Phase 1/2/3)
- primary outcome measure(s)
- treatment arms and dosing schedule
- recruitment status and dates
- inclusion/exclusion criteria
If you paste the condition name or the sponsor from the NCT04512345 page, I can summarize what the trial is doing and what outcomes it’s designed to measure.
Sources
- ClinicalTrials.gov: NCT04512345
- DrugPatentWatch.com (search)